ClinicalTrials.gg
CompletedNCT02422264Updated Jul 9, 2019Results posted

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

A Phase 4 interventional study of Infanrix hexa and Prevnar13 in Acellular Pertussis, Tetanus and Poliomyelitis, sponsored by GlaxoSmithKline. Completed at 30 sites in 6 countries. Open to participants aged 6 Weeks to 14 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-09.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
601
Allocation
Non-randomized
Ages
6 Weeks to 14 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Tetanus — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Tetanus.

Enrollment
4th of 15
601 · median 494
Started
2016
with 1 other
Phase 4
6 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
14 of 15
GlaxoSmithKline

Among the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Tetanus, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 4, and was the 13th registered.

Tetanus

319 studies on the registry are indexed under Tetanus; 30 are open to participants now.

Browse Tetanus studies →

Open to participants now

None of the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Tetanus is open now. The open studies under Tetanus, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 6 Weeks to 14 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Tetanus as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' Infanrix hexa, given in the primary vaccination schedule to infants born to pregnant women who participated in study 116945 [DTPA (BOOSTRIX)-047]. This study will help us evaluate if the presence of transplacentally transferred maternal antibodies interfere with the immune response to primary vaccination with Infanrix hexa and a co-administered pneumococcal conjugate vaccine given as a part of this study in infants.

03

Conditions studied

  • Acellular Pertussis
  • Tetanus
  • Poliomyelitis
  • Diphtheria
  • Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines
04

Who can participate

Ages eligible
6 Weeks to 14 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
  • Written obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
  • A male or female between, 6 and 14 weeks of age (including 6 weeks and up to and including 14 weeks and 6 days of age) at the time of the first vaccination.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Born to a mother enrolled in study 116945 [DTPA (BOOSTRIX)-047].
  • Medically stable* prematurely born infants, born after a gestation period of 27-36 weeks may be enrolled in the study at the discretion of the investigator.

    • Medically stable refers to the condition of premature infants who do not require significant medical support or ongoing management for debilitating disease and who have demonstrated a clinical course of sustained recovery by the time they receive the first dose of study vaccine.

Exclusion criteria

Exclusion Criteria:

  • Child in care
  • Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs during the period starting at birth prior to the first vaccine dose. For , this will mean prednisone ≥0.5mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab).
  • Administration of any chronic drug therapy to be continued during the study period.
  • A vaccine not foreseen by the study protocol administered during the period starting from 30 days before each dose of vaccine and ending 30 days after*, with the exception of inactivated influenza vaccine and other vaccines given as a part of the national/regional immunisation schedule, that are allowed at any time during the study period.

    • In case an emergency mass vaccination for an unforeseen public health threat (e.g.: a pandemic) is organised by the public health authorities, outside the routine immunisation program, the time period described above can be reduced if necessary for that vaccine provided it is licensed and used according to its SPC or package insert (PI) and according to the local governmental recommendations and provided a written approval of the Sponsor is obtained.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an or a non-investigational vaccine/product (pharmaceutical product or device).
  • Previous vaccination against Hib, diphtheria, tetanus, pertussis, pneumococcus, and/or poliovirus since birth.
  • History of Hib, diphtheria, tetanus, pertussis, pneumococcal, poliovirus and diseases.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition including severe combined immunodeficiency disease (SCID), based on medical history and physical examination (no laboratory testing required).
  • Family history of congenital or hereditary immunodeficiency.
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Major congenital defects
  • Serious chronic illness.
  • History of any neurological disorders or seizures.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥37.5°C/99.5°F for oral, axillary or tympanic route, or ≥38.0°C/100.4°F for rectal route.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products during the period starting at birth before the first dose of study vaccines or planned administration during the study period.
  • Hypersensitivity to latex.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
601 participants (actual)

Study arms

  • Experimental
    dTpa Group

    This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 \[DTPA (BOOSTRIX)-047\] i.e. who received a single dose of BoostrixTM during pregnancy and a dose of placebo immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.

    Biological: Infanrix hexa · Drug: Prevnar13

  • Active comparator
    Control Group

    This group will consist of infants born to mothers belonging to the Control group in study 116945 \[DTPA (BOOSTRIX)-047\], i.e. who received a single dose of placebo during pregnancy and a dose of BoostrixTM immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.

    Biological: Infanrix hexa · Drug: Prevnar13

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Vaccine Response Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens

    Vaccine response to the PT, FHA and PRN antigens, is defined as the appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations lower than (\<) the cut-off value of the assay), or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations greater than or equal to (≥) the cut-off value of the assay). Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, 2.187 IU/mL for anti-PRN.

    Time frame: 1 month after the last dose of the primary vaccination

  2. Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentration Above or Equal to the Assay Cut-off

    A seroprotected subject is a subject whose antibody concentration/titre was ≥ the level defining clinical protection, of 0.1 International Units per milliliter (IU/mL).

    Time frame: 1 month after the last dose of the primary vaccination

  3. Number of Seroprotected Subjects With Anti Hepatitis B (Anti-HBs) Antibody Concentration Above or Equal to the Assay Cut-off

    A seroprotected subject is a subject whose antibody concentration/titre was ≥ to the level defining clinical protection, of 10 micro International Units per milliliter (mIU/mL).

    Time frame: 1 month after the last dose of the primary vaccination

  4. Number of Seroprotected Subjects With Anti-poliovirus Type 1, 2 and 3 Antibody Concentration Above or Equal to 8

    A seroprotected subject is a subject whose antibody titre was ≥ the level defining clinical protection, of 8 ED50.

    Time frame: 1 month after the last dose of the primary vaccination

  5. Number of Seroprotected Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Above or Equal to the Assay Cut-off

    A seroprotected subject is a subject whose antibody concentration/titre was ≥ the level defining clinical protection, of 0.15 micrograms per milliliter (µg/mL).

    Time frame: 1 month after the last dose of the primary vaccination

Secondary outcomes

  1. Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T) Antibody Concentration Above or Equal to the Assay Cut-off.

    A seroprotected subject is a subject whose antibody concentration was ≥ the level defining clinical protection, of 0.1 IU/mL.

    Time frame: Before the first dose of Infanrix hexa

  2. Anti-D and Anti-T Antibody Concentrations

    Antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in IU/mL.

    Time frame: Before the first dose of Infanrix hexa

  3. Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentration Above or Equal to the Assay Cut-off.

    A seropositive subject is a subject whose antibody concentration is ≥ the assay cut-off defined. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA,2.187 IU/mL for anti-PRN

    Time frame: Before the first dose of Infanrix hexa

  4. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    Anti-PT, anti-FHA and anti-PRN antibody concentrations were expressed as GMCs and measured in IU/mL.

    Time frame: Before the first dose of Infanrix hexa

  5. Anti-D and Anti-T Antibody Concentrations

    Antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in IU/mL.

    Time frame: 1 month after the last dose of the primary vaccination

  6. Anti-Polio Type 1, 2 and 3 Antibody Titers

    Anti-Polio type 1, 2 and 3 antibody titers were expressed as geometric mean titers (GMT).

    Time frame: 1 month after the last dose of the primary vaccination

  7. Anti-HBs Antibody Concentrations

    Anti-HBs antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in mIU/mL.

    Time frame: 1 month after the last dose of the primary vaccination

  8. Anti-PRP Antibody Concentrations

    Anti-PRP antibody concentrations were expressed as GMCs and measured in µg/mL.

    Time frame: 1 month after the last dose of the primary vaccination

  9. Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations

    Anti-PT, anti-FHA, anti-PRN antibody concentrations were expressed as GMCs and measured in IU/mL.

    Time frame: 1 month after the last dose of the primary vaccination

  10. Anti-pneumococcal Antibody Concentrations

    Assessed anti-pneumococcal serotypes were (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), expressed as GMCs and measured in µg/mL.

    Time frame: 1 month after the last dose of the primary vaccination

  11. Number of Subjects With Anti-PT, Anti-FHA, Anti-PRN Antibody Concentration Above or Equal to the Assay Cut-off.

    A seropositive subject is a subject whose antibody concentration is ≥ the assay cut-off defined. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA,2.187 IU/mL for anti-PRN

    Time frame: 1 month after the last dose of the primary vaccination

  12. Number of Subjects With Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Solicited local symptoms were assessed by each and across dose.

    Time frame: During the 4-day (Day 0-Day 3) follow-up period after each vaccination

  13. Number of Subjects With Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and fever \[defined as axillary route temperature ≥ 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Solicited general symptoms were assessed by each and across dose.

    Time frame: During the 4-day (Day 0-Day 3) follow-up period after each vaccination

  14. Number of Subjects With Unsolicited Adverse Events

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 31-day (days 0-30) follow-up period after each vaccination

  15. Number of Subjects With Serious Adverse Events (SAEs)

    SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.

    Time frame: From Day 0, prior to vaccination until the study end, at Month 3 or 5 (depending on vaccination schedule of the country)

07

Results

Posted Jun 10, 2019

Participant flow

Participant flow — Overall Study
MilestonedTpa GroupControl Group
Started296305
Completed291301
Not completed54
Withdrew: Serious adverse event10
Withdrew: Withdrawal by subject12
Withdrew: Migrated/moved from study area31
Withdrew: Subject vaccinated outside of the study01

Outcome measures

PrimaryNumber of Subjects With Vaccine Response Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens

Vaccine response to the PT, FHA and PRN antigens, is defined as the appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations lower than (\<) the cut-off value of the assay), or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations greater than or equal to (≥) the cut-off value of the assay). Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, 2.187 IU/mL for anti-PRN.

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Response Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens
ParticipantsdTpa GroupControl Group
anti-PT antibody185249
anti-FHA antibody95238
anti-PRN antibody90225
PrimaryNumber of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentration Above or Equal to the Assay Cut-off

A seroprotected subject is a subject whose antibody concentration/titre was ≥ the level defining clinical protection, of 0.1 International Units per milliliter (IU/mL).

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentration Above or Equal to the Assay Cut-off
ParticipantsdTpa GroupControl Group
anti-D antibody264271
anti-T antibody266271
PrimaryNumber of Seroprotected Subjects With Anti Hepatitis B (Anti-HBs) Antibody Concentration Above or Equal to the Assay Cut-off

A seroprotected subject is a subject whose antibody concentration/titre was ≥ to the level defining clinical protection, of 10 micro International Units per milliliter (mIU/mL).

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects With Anti Hepatitis B (Anti-HBs) Antibody Concentration Above or Equal to the Assay Cut-off
ParticipantsdTpa GroupControl Group
Number of Seroprotected Subjects With Anti Hepatitis B (Anti-HBs) Antibody Concentration Above or Equal to the Assay Cut-off251259
PrimaryNumber of Seroprotected Subjects With Anti-poliovirus Type 1, 2 and 3 Antibody Concentration Above or Equal to 8

A seroprotected subject is a subject whose antibody titre was ≥ the level defining clinical protection, of 8 ED50.

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects With Anti-poliovirus Type 1, 2 and 3 Antibody Concentration Above or Equal to 8
ParticipantsdTpa GroupControl Group
anti-Polio 1 antibody233242
anti-Polio 2 antibody239235
anti-Polio 3 antibody228236
PrimaryNumber of Seroprotected Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Above or Equal to the Assay Cut-off

A seroprotected subject is a subject whose antibody concentration/titre was ≥ the level defining clinical protection, of 0.15 micrograms per milliliter (µg/mL).

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Above or Equal to the Assay Cut-off
ParticipantsdTpa GroupControl Group
Number of Seroprotected Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Above or Equal to the Assay Cut-off255256
SecondaryNumber of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T) Antibody Concentration Above or Equal to the Assay Cut-off.

A seroprotected subject is a subject whose antibody concentration was ≥ the level defining clinical protection, of 0.1 IU/mL.

Time frame:
Before the first dose of Infanrix hexa
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T) Antibody Concentration Above or Equal to the Assay Cut-off.
ParticipantsdTpa GroupControl Group
anti-D antibody200110
anti-T antibody240225
SecondaryAnti-D and Anti-T Antibody Concentrations

Antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in IU/mL.

Time frame:
Before the first dose of Infanrix hexa
Reported as:
Geometric mean · IU/mL
Anti-D and Anti-T Antibody Concentrations
IU/mLdTpa GroupControl Group
anti-D antibody0.423 (0.354 to 0.506)0.089 (0.076 to 0.103)
anti-T antibody2.152 (1.925 to 2.406)0.378 (0.330 to 0.434)
SecondaryNumber of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentration Above or Equal to the Assay Cut-off.

A seropositive subject is a subject whose antibody concentration is ≥ the assay cut-off defined. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA,2.187 IU/mL for anti-PRN

Time frame:
Before the first dose of Infanrix hexa
Reported as:
Count of participants · Participants
Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentration Above or Equal to the Assay Cut-off.
ParticipantsdTpa GroupControl Group
anti-PT antibody21888
anti-FHA antibody242210
anti-PRN antibody231151
SecondaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

Anti-PT, anti-FHA and anti-PRN antibody concentrations were expressed as GMCs and measured in IU/mL.

Time frame:
Before the first dose of Infanrix hexa
Reported as:
Geometric mean · IU/ml
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
IU/mldTpa GroupControl Group
anti-PT antibody11.9 (10.3 to 13.6)2.2 (2.0 to 2.5)
anti-FHA antibody88.3 (77.7 to 100.4)6.6 (5.7 to 7.7)
anti-PRN antibody70.5 (56.1 to 88.5)4.5 (3.7 to 5.4)
SecondaryAnti-D and Anti-T Antibody Concentrations

Antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in IU/mL.

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Geometric mean · IU/ml
Anti-D and Anti-T Antibody Concentrations
IU/mldTpa GroupControl Group
anti-D antibody1.747 (1.598 to 1.910)2.746 (2.502 to 3.015)
anti-T antibody2.347 (2.135 to 2.582)2.278 (2.069 to 2.508)
SecondaryAnti-Polio Type 1, 2 and 3 Antibody Titers

Anti-Polio type 1, 2 and 3 antibody titers were expressed as geometric mean titers (GMT).

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Geometric mean · Titers
Anti-Polio Type 1, 2 and 3 Antibody Titers
TitersdTpa GroupControl Group
anti-Polio 1 antibody432.1 (351.8 to 530.9)489.9 (402.6 to 596.0)
anti-Polio 2 antibody424.6 (342.7 to 526.2)388.4 (306.3 to 492.6)
anti-Polio 3 antibody730.6 (596.5 to 894.9)775.6 (645.9 to 931.3)
SecondaryAnti-HBs Antibody Concentrations

Anti-HBs antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in mIU/mL.

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Geometric mean · mIU/ml
Anti-HBs Antibody Concentrations
mIU/mldTpa GroupControl Group
Anti-HBs Antibody Concentrations1322.8 (1116.7 to 1567.0)1339.2 (1132.8 to 1583.3)
SecondaryAnti-PRP Antibody Concentrations

Anti-PRP antibody concentrations were expressed as GMCs and measured in µg/mL.

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Geometric mean · µg/mL
Anti-PRP Antibody Concentrations
µg/mLdTpa GroupControl Group
Anti-PRP Antibody Concentrations1.862 (1.554 to 2.231)1.717 (1.428 to 2.064)
SecondaryAnti-PT, Anti-FHA, Anti-PRN Antibody Concentrations

Anti-PT, anti-FHA, anti-PRN antibody concentrations were expressed as GMCs and measured in IU/mL.

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Geometric mean · IU/mL
Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations
IU/mLdTpa GroupControl Group
anti-PT antibody32.7 (30.2 to 35.3)54.7 (51.0 to 58.6)
anti-FHA antibody68.5 (63.5 to 73.9)103.5 (95.6 to 112.1)
anti-PRN antibody60.5 (54.2 to 67.6)92.0 (81.6 to 103.6)
SecondaryAnti-pneumococcal Antibody Concentrations

Assessed anti-pneumococcal serotypes were (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), expressed as GMCs and measured in µg/mL.

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Geometric mean · µg/mL
Anti-pneumococcal Antibody Concentrations
µg/mLdTpa GroupControl Group
anti-PnPS 1 antibody1.61 (1.43 to 1.80)1.92 (1.73 to 2.14)
anti-PnPS 3 antibody0.54 (0.49 to 0.60)0.60 (0.55 to 0.67)
anti-PnPS 4 antibody1.20 (1.07 to 1.35)1.56 (1.40 to 1.75)
anti-PnPS 5 antibody1.09 (0.96 to 1.24)1.27 (1.13 to 1.43)
anti-PnPS 6A antibody2.16 (1.89 to 2.47)2.59 (2.27 to 2.95)
anti-PnPS 6B antibody1.37 (1.12 to 1.68)1.44 (1.20 to 1.73)
anti-PnPS 7F antibody2.39 (2.15 to 2.65)2.67 (2.43 to 2.93)
anti-PnPS 9V antibody1.33 (1.19 to 1.50)1.64 (1.47 to 1.83)
anti-PnPS 14 antibody5.70 (4.99 to 6.52)6.57 (5.71 to 7.56)
anti-PnPS 18C antibody1.61 (1.42 to 1.82)1.79 (1.59 to 2.01)
anti-PnPS 19A antibody1.61 (1.43 to 1.82)2.01 (1.78 to 2.27)
anti-PnPS 19F antibody2.57 (2.35 to 2.82)3.24 (2.92 to 3.60)
anti-PnPS 23F antibody0.86 (0.74 to 0.99)1.02 (0.88 to 1.17)
SecondaryNumber of Subjects With Anti-PT, Anti-FHA, Anti-PRN Antibody Concentration Above or Equal to the Assay Cut-off.

A seropositive subject is a subject whose antibody concentration is ≥ the assay cut-off defined. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA,2.187 IU/mL for anti-PRN

Time frame:
1 month after the last dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Anti-PT, Anti-FHA, Anti-PRN Antibody Concentration Above or Equal to the Assay Cut-off.
ParticipantsdTpa GroupControl Group
anti-PT antibody266271
anti-FHA antibody266271
anti-PRN antibody266269
SecondaryNumber of Subjects With Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Solicited local symptoms were assessed by each and across dose.

Time frame:
During the 4-day (Day 0-Day 3) follow-up period after each vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms
ParticipantsdTpa GroupControl Group
Any Pain, Dose 1120120
Any Redness, Dose 1128116
Any Swelling, Dose 18187
Any Pain, Dose 2109101
Any Redness, Dose 2139139
Any Swelling, Dose 29895
Any Pain, Dose 38594
Any Redness, Dose 3122134
Any Swelling, Dose 377109
Any Pain, Across Doses175184
Any Redness, Across Doses205203
Any Swelling, Across Doses157168
SecondaryNumber of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and fever \[defined as axillary route temperature ≥ 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Solicited general symptoms were assessed by each and across dose.

Time frame:
During the 4-day (Day 0-Day 3) follow-up period after each vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms
ParticipantsdTpa GroupControl Group
Any Drowsiness, Dose 1166174
Any Irritability / Fussiness, Dose 1187191
Any Loss of Appetite, Dose 18594
Any Temperature/(Axillary) (≥37.5°C), Dose 16469
Any Drowsiness, Dose 2142149
Any Irritability / Fussiness, Dose 2182194
Any Loss of Appetite, Dose 26994
Any Temperature/(Axillary) (≥37.5°C), Dose 26276
Any Drowsiness, Dose 399104
Any Irritability / Fussiness, Dose 3142161
Any Loss of Appetite, Dose 36463
Any Temperature/(Axillary) (≥37.5°C), Dose 35247
Any Drowsiness, Across Doses216232
Any Irritability/Fussiness, Across Doses255257
Any Loss of appetite, Across Doses142157
Any Temperature/(Axillary) (≥37.5°C), Across Doses125126
SecondaryNumber of Subjects With Unsolicited Adverse Events

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 31-day (days 0-30) follow-up period after each vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events
ParticipantsdTpa GroupControl Group
Number of Subjects With Unsolicited Adverse Events161173
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.

Time frame:
From Day 0, prior to vaccination until the study end, at Month 3 or 5 (depending on vaccination schedule of the country)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsdTpa GroupControl Group
Number of Subjects With Serious Adverse Events (SAEs)717

Adverse events

Collected over Solicited symptoms were collected during the 4-day (Day 0-Day 3) follow-up period after each vaccination. Unsolicited AEs were collected during the 31-day (days 0-30) follow-up period after each vaccination. SAEs were collected from Day 0 to Month 3 or 5.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
dTpa Group0/296 (0%)7/296 (2.4%)292/296 (98.6%)
Control Group0/305 (0%)17/305 (5.6%)294/305 (96.4%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventdTpa GroupControl Group
BronchiolitisInfections and infestations1/2964/305
Congenital cytomegalovirus infectionCongenital, familial and genetic disorders1/2960/305
Ear malformationCongenital, familial and genetic disorders1/2960/305
Intestinal haemorrhageGastrointestinal disorders1/2960/305
Milk allergyImmune system disorders1/2960/305
Urinary tract infectionInfections and infestations1/2961/305
Skull fractureInjury, poisoning and procedural complications1/2960/305
Skull fractured baseInjury, poisoning and procedural complications1/2960/305
Altered state of consciousnessNervous system disorders1/2960/305
CraniosynostosisCongenital, familial and genetic disorders0/2961/305
Most frequent other events
Showing 10 of 132
Most frequent other events
EventdTpa GroupControl Group
Irritability postvaccinalGeneral disorders255/296257/305
SomnolenceNervous system disorders216/296232/305
Injection site erythemaGeneral disorders205/296203/305
Injection site painGeneral disorders175/296184/305
Injection site swellingGeneral disorders157/296169/305
Decreased appetiteMetabolism and nutrition disorders142/296157/305
PyrexiaGeneral disorders133/296139/305
Upper respiratory tract infectionInfections and infestations36/29632/305
NasopharyngitisInfections and infestations20/29615/305
TeethingGastrointestinal disorders14/29614/305

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)dTpa GroupControl GroupTotal
Mean8.7 ± 1.68.9 ± 1.88.8 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)dTpa GroupControl GroupTotal
Female141144285
Male155161316
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)dTpa GroupControl GroupTotal
African Heritage / African American4913
Asian - East Asian Heritage202
Asian - South East Asian Heritage303
White - Arabic / North African Heritage134
White - Caucasian / European Heritage268285553
Mixed origin18826
08

Study locations

30 sites
  • GSK Investigational Site
    Carlton, Victoria 3053, Australia
  • GSK Investigational Site
    Calgary, Alberta T3B 6A8, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1C5, Canada
  • GSK Investigational Site
    Brno, 613 00, Czechia
  • GSK Investigational Site
    Hradec Kralove, 500 02, Czechia
  • GSK Investigational Site
    Ostrava - Vitkovice, 703 84, Czechia
  • GSK Investigational Site
    Praha 4, 140 59, Czechia
  • GSK Investigational Site
    Praha, 14700, Czechia
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Seinajoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Milano, Lombardia 20122, Italy
  • GSK Investigational Site
    Milano, Lombardia 20142, Italy
  • GSK Investigational Site
    Milano, Lombardia 20154, Italy
  • GSK Investigational Site
    Novara, Piemonte 28100, Italy
  • GSK Investigational Site
    Torino, Piemonte 10126, Italy
  • GSK Investigational Site
    Malaga, Andalucia 29004, Spain
  • GSK Investigational Site
    Antequera/Málaga, 29200, Spain
  • GSK Investigational Site
    Aravaca, 28023, Spain
  • GSK Investigational Site
    Burgos, 09006, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Madrid, 28050, Spain
  • GSK Investigational Site
    Majadahonda (Madrid), 28222, Spain
  • GSK Investigational Site
    Móstoles, 28938, Spain
  • GSK Investigational Site
    Santiago de Compostela, 15706, Spain
  • GSK Investigational Site
    Sevilla, 41014, Spain
09

References and documents

Publications

  • Perrett KP, Halperin SA, Nolan T, Carmona Martinez A, Martinon-Torres F, Garcia-Sicilia J, Virta M, Vanderkooi OG, Zuccotti GV, Manzoni P, Kostanyan L, Meyer N, Ceregido MA, Cheuvart B, Kuriyakose SO, Stranak Z, Merino Arribas JM, Cilleruelo Ortega MJ, Miranda-Valdivieso M, Arias Novas B, Ramos Amador JT, Omenaca F, Baca M, Marchisio PG, Mesaros N. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. Vaccine. 2020 Feb 18;38(8):2105-2114. doi: 10.1016/j.vaccine.2019.10.104. Epub 2019 Nov 24. PubMed 31776027 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Mar 2018, 25 months.

Results were first posted in Jun 2019, 1 year 3 months after primary completion.

Of 19 phase 4 interventional studies under Tetanus, half reached primary completion within 22 months of starting (the median); a quarter within 6 and three quarters within 30. This study's 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2015
First posted
Apr 21, 2015
StartActual
Jan 22, 2016
Primary completionActual
Mar 7, 2018
CompletionActual
Mar 7, 2018
Results first posted
Jun 10, 2019
Last update
Jul 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02422264
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 21, 2015
Start date
Jan 22, 2016
Primary completion
Mar 7, 2018
Completion
Mar 7, 2018
Results posted
Jun 10, 2019
Last update
Jul 9, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion